BeiGene Granted US Regulatory Nod for TEVIMBRA® to Treat Progressive or Spread Esophageal Cancer Post-Chemotherapy.

Ionis has disclosed encouraging outcomes from its second-phase trial of ION224, a drug currently being tested which shows promise in addressing NASH/MASH conditions.

Silence Therapeutics Reveals Encouraging Preliminary Results at 36 Weeks from Active Phase 2 Trial with Zerlasiran in Subjects with Elevated Lipoprotein(a) Levels.

Takeda Reveals Encouraging Initial Outcomes of Phase 2 Trial for Mezagitamab (TAK-079), an Emerging Leading Anti-CD38 Monoclonal Antibody, in Treating Primary Immune Thrombocytopenia.

Pfizer Reveals Favorable Survival Data from Stage III Study of ADCETRIS® for Recurrent/Resistant Large B-cell Lymphoma Treatment.

At the 2024 AAD conference, Longbio Pharma showcased encouraging early-stage findings for their drug LP-003.

10xBio Reveals Interim Phase 2b Trial Outcomes Indicate Enhanced Effectiveness of New Treatment in Submental Fat Reduction.

Initial stage of the onCARlytics study focusing on solid cancers moves forward to explore combined therapeutic approaches.

Johnson & Johnson has filed a supplementary application with the FDA for the authorization of TREMFYA® (guselkumab) aimed at treating moderate to severe ulcerative colitis in adults.

Domain Therapeutics and Chime Biologics have entered into a production deal to push forward a new CCR8-targeting antibody for use in treating cancer through immunotherapy.

Monte Rosa Therapeutics has commenced preclinical trials for its novel compound MRT-8102, a pioneering NEK7-targeted molecular glue degrader with additional capabilities of impeding the NLRP3/IL-1β signaling cascade.

Aprea Therapeutics reveals it has received FDA authorization for its investigational new drug, APR-1051, a novel WEE1 kinase blocker targeting cancers with high Cyclin E levels.